CN115093323B - β-官能团化手性高烯丙醇衍生物及其制备方法与应用 - Google Patents

β-官能团化手性高烯丙醇衍生物及其制备方法与应用 Download PDF

Info

Publication number
CN115093323B
CN115093323B CN202210904637.8A CN202210904637A CN115093323B CN 115093323 B CN115093323 B CN 115093323B CN 202210904637 A CN202210904637 A CN 202210904637A CN 115093323 B CN115093323 B CN 115093323B
Authority
CN
China
Prior art keywords
reaction
product
iridium
beta
chiral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210904637.8A
Other languages
English (en)
Other versions
CN115093323A (zh
Inventor
王春江
董秀琴
易智远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan University WHU
Original Assignee
Wuhan University WHU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan University WHU filed Critical Wuhan University WHU
Priority to CN202210904637.8A priority Critical patent/CN115093323B/zh
Publication of CN115093323A publication Critical patent/CN115093323A/zh
Application granted granted Critical
Publication of CN115093323B publication Critical patent/CN115093323B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明提供一种β‑官能团化手性高烯丙醇衍生物的制备方法，包括以下步骤：在惰性气体保护下，在溶剂中加入底物1、底物2、铱催化剂、0.01～10当量的碱，于在‑20～110℃反应0.1～96小时，即得到β‑官能团化手性高烯丙醇衍生物。本发明还提供β‑官能团化手性高烯丙醇衍生物在合成Taniguchi lactone或cytisine合成前体中的应用。本发明提供的制备方法合成简单、成本低、产率高，且反应目标化合物对映选择性好。该制备方法能够容忍非常多类型的底物，包含多种重要官能团，包括药物化学中重要的杂环类底物，能够轻易转化成其他有用基团。制得的β‑官能团化手性高烯丙醇衍生物在制备具有β‑官能团化高烯丙醇结构单元的抗抑郁类药物、抗肿瘤类药物或天然产物中，具有广阔的推广及应用前景。

Description

β-官能团化手性高烯丙醇衍生物及其制备方法与应用
技术领域
本发明属于医药化学技术领域，具体涉及一种β-官能团化手性高烯丙醇衍生物的制备方法，还涉及一种β-官能团化手性高烯丙醇衍生物的应用。
背景技术
β-官能团化高烯丙醇是众多具有显著生物活性的天然产物和候选药物中的关键结构核心之一。获得这些关键β-官能团化高烯丙醇衍生物的典型合成方法需要解决两个挑战：其一，通过简洁的合成策略有序引入多个官能团，如羰基、烯基和受保护的醇；其二，不对称转化过程中立体选择性的出色控制。
常规的β-官能团化高烯丙醇衍生物通常采用金属催化或者有机合成的方法进行制备。上述制备方法合成步骤较为繁琐，存在着底物范围较窄、操作复杂、合成效率较低等问题，限制了β-官能团化高烯丙醇衍生物在天然产物或药物分子合成上的应用。此外，尚未有关于手性β-官能团化高烯丙醇化合物的合成方法的相关报道。
基于此，开发一种新的不对称催化方法来获得这些具有高立体控制和原子经济性的有用的手性β-官能团化高烯丙醇，是亟需解决的技术问题。
发明内容
本发明的目的之一在于提供一种制备方法简单、成本低、产率高，且反应目标化合物对映选择性好的β-官能团化手性高烯丙醇衍生物的制备方法。
本发明的目的之二在于提供一种β-官能团化手性高烯丙醇衍生物在合成Taniguchi lactone以及/>或cytisine合成前体/>中的应用。
本发明实现目的之一采用的技术方案是：提供一种β-官能团化手性高烯丙醇衍生物的制备方法，包括以下步骤：
在惰性气体保护下，在溶剂中加入底物1、底物2、铱催化剂、0.01～10当量的碱，于在-20～110℃反应0.1～96小时，即得到β-官能团化手性高烯丙醇衍生物，反应式如下：
其中，
R1为取代或未取代的芳基、取代或未取代的杂芳基、烷基中的一种；
R2为硝基、羰基、磺酰基、取代的磺酰胺基、亚磺酰基、取代的亚磺酰胺基、酯基、取代的酰胺基、取代或未取代的杂芳基中的一种；
R3为H或F；
*表示手性碳原子的位置。
所述取代的芳基的取代基为卤素、硝基、酚羟基、取代的磺酰胺、取代的硅基、烷基、烷氧基、氧羰基、氮羰基、-CF3、-CN或取代的氨基中的一种；
所述取代的杂芳基的取代基为卤素、硝基、酚羟基、取代的磺酰胺、取代的硅基、烷基、烷氧基、氧羰基、氮羰基、-CF3、-CN或取代的氨基中的一种。
进一步的，当R2为硝基、羰基、磺酰基、取代的磺酰胺基、亚磺酰基、取代的亚磺酰胺基时，R3为H或F；当R2为酯基、取代的酰胺基、取代或未取代的杂芳基时，R3为H。
具体地，当R2为酯基、取代的酰胺基、取代或未取代的杂芳基中的一种(以R4表示)，R3为H时，反应式如下式II所示：
其中，
R1为取代或未取代的芳基、取代或未取代的杂芳基、烷基，R4为酯基、取代的酰胺基、取代或未取代的杂芳基，*表示手性碳原子的位置。
在上述条件下，所述β-官能团化手性高烯丙醇衍生物的制备方法还包括：对反应体系内的底物1的含量进行监测，当所述底物1完全转化后，向反应体系内加入四丁基氟化铵，并于25～60℃继续反应0.1～96小时；所述四丁基氟化铵的用量为底物1的2～20当量。经研究发现，当R2为酯基、取代的酰胺基、取代或未取代的杂芳基中的一种时，反应很容易停留在中间体阶段，对反应的最终转化率造成不利影响，在本发明中，通过在底物1(底物3)完全反应后，加入底物1(底物3)的2～20当量的四丁基氟化铵，能够有效的促进中间体到最终产物的转化，进而提高反应转化率。
进一步的，所述底物1或底物3的浓度为0.001～3.0M，所述底物1或底物3与底物2的摩尔比为1:2～10；所述铱催化剂或铱络合物的用量为底物1或底物3的0.0001～10mol％。
进一步的，所述碱选自醇的碱金属盐、胺的碱金属盐、碱金属碳酸盐、碱金属氢氧化物或有机碱中的任一种。
所述醇的碱金属盐选自叔丁醇钾、叔丁醇钠、异丙醇钾、异丙醇钠中的一种或多种的组合；所述胺的碱金属盐选自二异丙基胺基锂、双三甲基硅基胺基锂、双三甲基硅基胺基钠、双三甲基硅基胺基钾中的一种或多种的组合；所述碱金属碳酸盐选自碳酸钾、碳酸钠、碳酸铯中的一种或多种的组合；所述碱金属氢氧化物选自氢氧化钾和/或氢氧化钠；所述有机碱为三乙胺、四甲基乙二胺、1,5-二氮杂二环[4.3.0]壬-5-烯、1,8-二氮杂二环十一碳-7-烯、1,4-二氮杂二环[2.2.2]辛烷、吡啶、4-二甲氨基吡啶、N-甲基吗啉、三乙烯二胺、四甲基胍、2-叔丁基-1,1,3,3-四甲基胍中的一种或多种的组合。
优选地，所述碱选自有机碱或碱金属碳酸盐。与其他种类的碱相比，有机碱或碱金属碳酸盐来源广、成本较低、使用方便、危害性较小。在本体系中，最终产物的提纯中，有机碱或碱金属碳酸盐也更易于去除。
进一步的，所述溶剂选自甲醇、乙醇、异丙醇、叔丁醇、仲丁醇、乙酸乙酯、乙酸异丁酯、乙酸异丙酯、正己烷、环己烷、正庚烷、丙酮、丁酮、乙醚、甲基叔丁基醚、甲基环戊基醚、甲基四氢呋喃、四氢呋喃、乙腈、二氯甲烷、三氯甲烷、1,2-二氯乙烷、二甲亚砜、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、甲苯和二氧六环中的一种或多种的组合。
进一步的，所述铱催化剂的制备方法可以是：将金属铱盐和手性配体L以1:2摩尔比溶于除氧四氢呋喃和除氧正丙胺的混合溶剂中，50℃下反应30分钟后，减压条件下蒸去溶剂，得到铱催化剂。该方法制得的铱催化剂属于活性中间体，需要现场制备及使用，无法长时间保存。使用时直接将其他反应原料加入含有铱催化剂的反应容器中。
在一些较好的实施方式中，所述铱催化剂包括铱络合物，所述铱络合物的制备方法包括：在20℃条件，将金属铱盐和手性配体L以1:2摩尔比溶于四氢呋喃中，反应0.5～1小时，加入2个当量的高氯酸银置换阴离子，随后加入4个当量的4-乙烯基-1,3-二氧环戊-2-酮，20℃反应20小时，将产物通过柱层析分离得到铱络合物。上述方法制备的铱络合物具有可预先反应制备、能够在空气条件下长期稳定储存的优势，相对于现场制备的铱催化剂而言，可直接与反应原料一同加入反应容器中，不仅使用更方便，而且能够节约实验所需时间，提高效率。
进一步的，所述金属铱盐选自[Ir(COD)Cl]2或[Ir(DBCOT)Cl]2；
所述手性配体L的结构式选自如下任一种：
在一些较好的实施方式中，所述手性配体L的结构式为：
经大量研究发现，在制备β-官能团化手性高烯丙醇衍生物的过程中，采用上述两种配体，产率及对映选择性相对更高。
本发明实现目的之二采用的技术方案是：提供一种基于本发明目的之一所述的β-官能团化手性高烯丙醇衍生物在合成Taniguchi lactone以及/>或cytisine合成前体/>中的应用。
在一些较好的实施方式中，所述Taniguchi lactone的制备方法，包括以下步骤：
将本发明目的之一所述的β-官能团化手性高烯丙醇衍生物置于浓硫酸中进行加热，所述β-官能团化手性高烯丙醇衍生物中，R1选自取代或未取代的芳基、取代或未取代的杂芳基、烷基中的一种、R2为酯基或酰胺基，R3为H；得到Taniguchi lactone，反应式如下：
在一些较好的实施方式中，所述cytisine合成前体的制备方法包括以下步骤：
S1、将本发明目的之一所述的β-官能团化手性高烯丙醇衍生物在醋酸中加热，所述β-官能团化手性高烯丙醇衍生物I中，R1选自取代或未取代的芳基、取代或未取代的杂芳基、烷基中的一种，R3为H，R2为硝基；加入锌粉，还原得到伯胺；将所述伯胺在二氯甲烷与三乙胺的存在下与丙烯酰氯反应得到酰胺，反应式如下：
S2、将步骤S1制得的酰胺在氢氧化钠中水解得到伯醇；将所述伯醇在氢氧化钠的作用下，与溴化苄反应得到苄基取代的丙烯酰胺，反应式如下：
S3、将步骤S2制得的苄基取代的丙烯酰胺在Grubbs(II)催化剂的存在下，在二氯甲烷中加热反应，反应得到cytisine合成前体环状丙烯酰胺，反应式如下：
应用本发明制得的β-官能团化高烯丙醇衍生物为原料来制备上述产物时，与常规合成方法相比，本发明的合成路线更短、合成效率更高，反应条件温和、合成方法简单，所得反应目标化合物的对应性好。
特别是在cytisine合成前体的制备过程中，常规方法均采用手性底物出发，制备过程中需要通过拆分来提高化合物的对映选择性。相比而言，本发明采用消旋体底物，采用不对称催化合成得到高对映选择性的产物，制备方法更简单快捷、产物纯度高。
进一步的，本发明还提供了根据本发明目的之一的制备方法制得的β-官能团化手性高烯丙醇衍生物、或根据本发明目的之二所述的制备方法制得的Taniguchi lactone或cytisine合成前体在制备抗抑郁类药物、抗肿瘤类药物中的应用。
与现有技术相比，本发明的有益效果为：
(1)本发明创造性地利用逆克莱森重排高立体选择性地反应得到β-官能团化高烯丙醇衍生物。与常规的合成方法相比，本发明提供给的制备方法合成简单，成本低，产率高，所得反应目标化合物对映选择性好，产率为60-98％，对映选择性过量>90％。
(2)本发明提供的制备方法，只需要使用商业可得的配体，方法整体简便易行，能够容忍非常多类型的底物，包括药物化学中重要的杂环类底物；该制备方法采用铱络合物作为催化剂，在反应中表现出催化反应速度快和催化剂用量低的优点。
(3)本发明提供的制备方法制得的β-官能团化高烯丙醇衍生物，含有多个重要官能团，可以轻易转化成其他有用基团，能作为原料合成大量的有效化合物，且可以制备出手性β-官能团化高烯丙醇。本发明制得的衍生物在制备具有β-官能团化高烯丙醇结构单元的抗抑郁类药物、抗肿瘤类药物或天然产物中，具有广阔的推广及应用前景。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动的前提下所获得的所有其他实施例，都属于本发明保护的范围。
需要说明的是，在不冲突的情况下，本发明中的实施例及实施例中的特征可以相互组合。
下面结合具体实施例对本发明作进一步说明，但不作为本发明的限定。
下列实施例中采用的手性配体(S,S,S)-L1的结构式为下列实施例中采用的配体(R,R,R)-L1的结构式为/>
实施例1
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol二苯甲酰基甲烷、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率85％，手性高效液相色谱测定产物的对映选择性过量97％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝6.07and 6.59min；[α]15 D＝-11.7(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.01–7.94(m,4H),7.60–7.51(m,2H),7.47–7.40(m,4H),5.89(ddd,J＝17.6,10.4,7.5Hz,1H),5.26–5.10(m,2H),4.43(dd,J＝10.9,6.0Hz,1H),4.36(dd,J＝10.9,6.4Hz,1H),3.41–3.32(m,1H),3.24(dd,J＝16.7,6.0Hz,1H),3.15(dd,J＝16.7,7.3Hz,1H).13C NMR(101MHz,Chloroform-d)δ198.2,166.4,137.4,137.0,133.2,133.0,130.1,129.6,128.6,128.4,128.1,116.9,66.9,40.0,38.5.HRMS(ESI+)计算值C19H19O3 +([M+H]+):295.1329,测量值:295.1325。
实施例2
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二对甲苯基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率85％，熔点40℃,手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralcel ID,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝252nm)；tr＝11.12and 12.85min；[α]15 D＝-10.3(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.91–7.82(m,4H),7.26–7.21(dd,J＝10.7,8.6Hz,4H),5.87(ddd,J＝17.6,10.4,7.5Hz,1H),5.23–5.03(m,2H),4.39(dd,J＝10.9,6.0Hz,1H),4.33(dd,J＝10.9,6.4Hz,1H),3.37–3.29(m,1H),3.20(dd,J＝16.6,6.0Hz,1H),3.10(dd,J＝16.6,7.5Hz,1H),2.40(s,3H),2.40(s,3H).13C NMR(101MHz,Chloroform-d)δ197.8,166.4,143.9,143.6,137.5,134.5,129.6,129.3,129.0,128.2,127.3,116.7,66.8,39.9,38.5,21.59,21.56.HRMS(ESI+)计算值C21H23O3 +([M+H]+):323.1642,测量值:323.1629。
实施例3
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二间甲苯基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率78％，手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak IE,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝10.46and 11.04min；[α]15 D＝-12.1(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.82–7.78(m,2H),7.77–7.71(m,2H),7.41–7.28(m,4H),5.88(ddd,J＝17.6,10.4,7.5Hz,1H),5.25–5.10(m,2H),4.41(dd,J＝10.9,5.9Hz,1H),4.33(dd,J＝10.9,6.6Hz,1H),3.41–3.30(m,1H),3.23(dd,J＝16.7,6.1Hz,1H),3.11(dd,J＝16.6,7.3Hz,1H),2.39(s,3H),2.39(s,3H).13C NMR(101MHz,Chloroform-d)δ198.4,166.6,138.4,138.1,137.4,137.0,133.9,133.7,130.1,130.0,128.6,128.5,128.2,126.7,125.3,116.8,66.9,40.1,38.5,21.3,21.2.HRMS(ESI+)计算值C21H23O3 +([M+H]+):323.1642,测量值:323.1640。
实施例4
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二邻甲苯基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率80％，手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝6.16and 6.62min；[α]15 D＝-9.9(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.91–7.85(m,1H),7.64–7.59(m,1H),7.43–7.33(m,2H),7.25–7.20(m,4H),5.86(ddd,J＝17.6,10.4,7.6Hz,1H),5.24–5.09(m,2H),4.39(dd,J＝10.9,6.1Hz,1H),4.32(dd,J＝10.9,6.0Hz,1H),3.35–3.24(m,1H),3.16(dd,J＝16.6,5.7Hz,1H),3.05(dd,J＝16.7,7.8Hz,1H),2.58(s,3H),2.47(s,3H).13C NMR(101MHz,Chloroform-d)δ202.2,167.4,140.2,138.2,137.9,137.6,132.0,131.7,131.3,130.5,129.5,128.3,125.7,125.6,116.9,66.8,42.9,38.7,21.8,21.2.HRMS(ESI+)计算值C21H23O3 +([M+H]+):323.1642,测量值:323.1637。
实施例5
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(4-甲氧基苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率85％，熔点56℃,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝10.40and15.95min；[α]15 D＝-10.2(c 1.00,CH2Cl2)；1H NMR(400MHz,CDCl3)δ7.98–7.92(m,4H),6.95–6.87(m,4H),5.87(ddd,J＝17.7,10.4,7.5Hz,1H),5.23–5.08(m,2H),4.38(dd,J＝10.9,6.1Hz,1H),4.32(dd,J＝10.9,6.4Hz,1H),3.86(s,3H),3.86(s,3H),3.37–3.28(m,1H),3.17(dd,J＝16.4,6.1Hz,1H),3.07(dd,J＝16.4,7.4Hz,1H).13C NMR(101MHz,Chloroform-d)δ196.7,166.1,163.5,163.3,137.6,131.6,130.3,130.1,122.5,116.6,113.7,113.6,66.7,55.41,55.37,39.6,38.6.HRMS(ESI+)计算值C21H23O5 +([M+H]+):355.1540,测量值:355.1529。
实施例6
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(3-甲氧基苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率83％,手性高效液相色谱测定产物的对映选择性过量93％，HPLC(ChiralpakAS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝9.47and10.26min；[α]15 D＝-11.8(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.61–7.56(m,1H),7.56–7.51(m,2H),7.49–7.45(m,1H),7.39–7.34(m,1H),7.34–7.29(m,1H),7.13–7.06(m,2H),5.87(ddd,J＝17.2,10.4,7.5Hz,1H),5.26–5.11(m,2H),4.41(dd,J＝10.9,6.0Hz,1H),4.35(dd,J＝10.9,6.5Hz,1H),3.83(s,6H),3.41–3.29(m,1H),3.22(dd,J＝16.7,6.1Hz,1H),3.12(dd,J＝16.7,7.2Hz,1H).13C NMR(101MHz,Chloroform-d)δ197.9,166.2,159.8,159.5,138.3,137.4,131.3,129.6,129.3,121.9,120.7,119.7,119.4,116.8,114.1,112.2,67.0,55.4,40.1,38.5.HRMS(ESI+)计算值C21H23O5 +([M+H]+):355.1540,测量值:355.1534。
实施例7
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(2-甲氧基苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率56％,手性高效液相色谱测定产物的对映选择性过量97％，HPLC(ChiralpakAS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝10.63and15.34min；[α]15 D＝-3.4(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.77(dd,J＝7.9,1.9Hz,1H),7.63(dd,J＝7.7,1.8Hz,1H),7.54–7.36(m,2H),7.06–6.86(m,4H),5.85(ddd,J＝17.5,10.4,7.3Hz,1H),5.19–5.06(m,2H),4.36(dd,J＝10.8,6.0Hz,1H),4.28(dd,J＝10.8,6.0Hz,1H),3.87(s,3H),3.87(s,3H),3.33–3.27(m,1H),3.27–3.20(m,1H),3.16–3.07(m,1H).13C NMR(101MHz,Chloroform-d)δ200.7,166.0,159.2,158.3,138.0,133.5,133.4,131.6,130.4,128.4,120.7,120.0,116.3,111.9,111.4,67.0,55.8,55.4,45.3,38.7.HRMS(ESI+)计算值C21H23O5 +([M+H]+):355.1540,测量值:355.1544。
实施例8
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(4-氟苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率84％,熔点45℃,手性高效液相色谱测定产物的对映选择性过量93％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝6.20and6.88min；[α]15 D＝-7.7(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.05–7.93(m,4H),7.16–7.06(m,4H),5.86(ddd,J＝17.6,10.4,7.5Hz,1H),5.26–5.11(m,2H),4.41(dd,J＝10.9,6.1Hz,1H),4.34(dd,J＝10.9,6.5Hz,1H),3.40–3.29(m,1H),3.18(dd,J＝16.8,6.2Hz,1H),3.10(dd,J＝16.8,7.1Hz,1H).13C NMR(101MHz,Chloroform-d)δ196.4,165.79(d,J＝256.5Hz),165.78(d,J＝254.5Hz),165.4,137.3,133.3(d,J＝3.0Hz),132.1(d,J＝9.5Hz),130.7(d,J＝9.1Hz),126.2(d,J＝3.0Hz),117.0,115.7(d,J＝22.1Hz),115.5(d,J＝22.1Hz),67.0,39.9,38.4.19F NMR(376MHz,Chloroform-d)δ-104.91,-105.47.HRMS(ESI+)计算值C19H17F2O3 +([M+H]+):331.1140,测量值:331.1125。
实施例9
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(3-氟苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率79％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝276nm)；tr＝5.57and 6.10min；[α]15 D＝-8.0(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.82–7.76(m,1H),7.75–7.71(m,1H),7.69–7.60(m,2H),7.48–7.36(m,2H),7.31–7.27(m,1H),7.26–7.20(m,1H),5.87(ddd,J＝17.6,10.4,7.5Hz,1H),5.27–5.12(m,2H),4.43(dd,J＝10.9,6.0Hz,1H),4.36(dd,J＝10.9,6.5Hz,1H),3.42–3.29(m,1H),3.19(dd,J＝16.9,6.3Hz,1H),3.11(dd,J＝16.9,7.1Hz,1H).13C NMR(101MHz,Chloroform-d)δ196.7(d,J＝2.2Hz),165.2(d,J＝3.5Hz),162.9(d,J＝249.6Hz),162.5(d,J＝248.3Hz),138.9(d,J＝6.0Hz),137.0,132.1(d,J＝7.4Hz),130.2(d,J＝30.9Hz),130.1(d,J＝31.4Hz),125.3(d,J＝3.0Hz),123.8(d,J＝3.0Hz),120.3(d,J＝21.4Hz),120.1(d,J＝21.3Hz),117.2,116.4(d,J＝23.4Hz),114.8(d,J＝22.2Hz),67.2,40.1,38.3.19F NMR(376MHz,Chloroform-d)δ-111.63,-112.26.HRMS(ESI+)计算值C19H17F2O3 +([M+H]+):331.1140,测量值:331.1136。
实施例10
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(2-氯苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率68％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝7.08and 7.48min；[α]15 D＝-4.5(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.81(dd,J＝7.8,1.6Hz,1H),7.47–7.35(m,5H),7.34–7.27(m,2H),5.85(ddd,J＝17.4,10.4,7.3Hz,1H),5.25–5.11(m,2H),4.45(dd,J＝11.0,5.5Hz,1H),4.34(dd,J＝10.9,5.8Hz,1H),3.34–3.23(m,2H),3.14(dd,J＝18.8,9.2Hz,1H).13C NMR(101MHz,Chloroform-d)δ201.3,165.6,139.3,136.9,133.7,132.6,131.8,131.5,131.1,130.8,130.5,130.0,129.0,126.9,126.6,117.3,67.4,44.4,38.5.HRMS(ESI+)计算值C19H17Cl2O3 +([M+H]+):363.0549,测量值:363.0538。
实施例11
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(4-溴苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率67％,熔点60℃，手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝252nm)；tr＝6.73and7.55min；[α]15 D＝-4.5(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.87–7.76(m,4H),7.64–7.53(m,4H),5.85(ddd,J＝17.6,10.4,7.5Hz,1H),5.29–5.04(m,2H),4.41(dd,J＝10.9,6.1Hz,1H),4.34(dd,J＝10.9,6.5Hz,1H),3.40–3.26(m,1H),3.16(dd,J＝16.8,6.3Hz,1H),3.08(dd,J＝16.8,7.1Hz,1H).13C NMR(101MHz,Chloroform-d)δ196.9,165.6,137.1,135.6,132.0,131.7,131.0,129.6,128.9,128.4,128.2,117.1,67.0,39.9,38.4.HRMS(ESI+)计算值C19H17Br2O3 +([M+H]+):452.9520,测量值:452.9516。
实施例12
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-双(4-(三氟甲基)苯基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率79％,熔点56℃，手性高效液相色谱测定产物的对映选择性过量91％，HPLC(Chiralcel OD-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝220nm)；tr＝6.83and 7.62min；[α]25 D＝-10.7(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.13–7.99(m,4H),7.75–7.63(m,4H),5.87(ddd,J＝17.7,10.4,7.6Hz,1H),5.30–5.13(m,2H),4.46(dd,J＝11.0,6.2Hz,1H),4.40(dd,J＝10.9,6.5Hz,1H),3.44–3.33(m,1H),3.23(dd,J＝17.0,6.3Hz,1H),3.16(dd,J＝17.0,7.0Hz,1H).13C NMR(101MHz,Chloroform-d)δ197.0,165.1,139.4,136.9,134.6(q,J＝32.6Hz),133.1,129.9,128.4,125.7(q,J＝3.7Hz),125.4(q,J＝3.8Hz),123.55(q,J＝273.9Hz),123.49(q,J＝273.7Hz),117.3,67.3,40.2,38.3.19F NMR(376MHz,Chloroform-d)δ-63.2.HRMS(ESI+)计算值C21H17F6O3 +([M+H]+):431.1076,测量值:431.1080。
实施例13
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二(萘-2-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率94％,熔点88℃，手性高效液相色谱测定产物的对映选择性过量90％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝13.81and26.19min；[α]15 D＝-1.6(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.54(d,J＝2.1Hz,1H),8.48(d,J＝1.8Hz,1H),8.03(ddd,J＝8.1,6.1,1.8Hz,2H),7.93–7.82(m,6H),7.62–7.55(m,2H),7.55–7.48(m,2H),5.96(ddd,J＝17.5,10.4,7.3Hz,1H),5.34–5.13(m,2H),4.54(dd,J＝10.9,5.8Hz,1H),4.46(dd,J＝10.9,6.5Hz,1H),3.53–3.46(m,1H),3.42(dd,J＝16.2,6.1Hz,1H),3.30(dd,J＝16.2,7.0Hz,1H).13C NMR(101MHz,Chloroform-d)δ198.1,166.6,137.5,135.6,135.5,134.3,132.5,132.4,131.1,129.8,129.5,129.3,128.5,128.2,128.1,127.7,127.3,126.8,126.6,125.2,123.8,117.0,67.1,40.2,38.8.HRMS(ESI+)计算值C27H23O3 +([M+H]+):395.1642,测量值:395.1647。
实施例14
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二(萘-1-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率85％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝300nm)；tr＝19.48and 21.59min；[α]15 D＝-17.8(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.88(dd,J＝8.6,1.2Hz,1H),8.63–8.46(m,1H),8.14(dd,J＝7.3,1.3Hz,1H),8.06–7.93(m,2H),7.91–7.80(m,3H),7.62–7.50(m,4H),7.49–7.42(m,2H),5.96(ddd,J＝17.6,10.4,7.5Hz,1H),5.31–5.14(m,2H),4.56(dd,J＝10.9,6.0Hz,1H),4.49(dd,J＝10.9,6.1Hz,1H),3.52–3.42(m,1H),3.38(dd,J＝16.4,5.8Hz,1H),3.25(dd,J＝16.4,7.7Hz,1H).13C NMR(101MHz,Chloroform-d)δ202.4,167.3,137.5,136.0,133.9,133.8,133.4,132.7,131.3,130.2,130.0,128.5,128.4,127.9,127.7,127.4,127.0,126.5,126.2,125.8,125.7,124.5,124.3,117.2,67.1,43.5,39.0.HRMS(ESI+)计算值C27H23O3 +([M+H]+):395.1642,测量值:395.1645。
实施例15
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二(吡啶-2-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率93％,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralcel OJ-H,i-propanol/hexane＝10/90,flow rate 0.8mL/min,λ＝262nm)；tr＝31.56and33.66min；[α]15 D＝-6.6(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.78–8.71(m,1H),8.68–8.62(m,1H),8.10–8.04(m,1H),8.03–7.97(m,1H),7.86–7.78(m,2H),7.50–7.41(m,2H),5.89(ddd,J＝17.3,10.4,7.1Hz,1H),5.25–5.09(m,2H),4.53(dd,J＝10.8,5.9Hz,1H),4.44(dd,J＝10.8,6.2Hz,1H),3.54–3.37(m,3H).13C NMR(101MHz,Chloroform-d)δ199.9,164.8,153.2,149.9,148.9,147.9,137.4,136.90,136.86,127.2,126.8,125.1,121.9,116.9,67.8,39.1,38.5.HRMS(ESI+)计算值C17H17N2O3 +([M+H]+):297.1234,测量值:297.1224。
实施例16
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二(呋喃-2-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率87％,手性高效液相色谱测定产物的对映选择性过量91％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝252nm)；tr＝9.95and11.84min；[α]15 D＝-1.7(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.57(d,J＝0.8Hz,1H),7.56(d,J＝0.8Hz,1H),7.20(dd,J＝3.6,0.8Hz,1H),7.13(dd,J＝3.5,0.9Hz,1H),6.52(dd,J＝3.5,1.7Hz,1H),6.49(dd,J＝3.5,1.8Hz,1H),5.82(ddd,J＝17.7,10.4,7.6Hz,1H),5.25–5.07(m,2H),4.39(dd,J＝10.9,6.0Hz,1H),4.30(dd,J＝10.9,6.7Hz,1H),3.36–3.23(m,1H),3.06(dd,J＝16.0,6.4Hz,1H),2.98(dd,J＝16.0,7.5Hz,1H).13CNMR(101MHz,Chloroform-d)δ187.3,158.4,152.7,146.4,146.4,144.4,136.8,118.0,117.2,117.1,112.3,111.8,66.7,39.9,38.5.HRMS(ESI+)计算值C15H15O5 +([M+H]+):275.0914,测量值:275.0910。
实施例17
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二(噻吩-2-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率72％,手性高效液相色谱测定产物的对映选择性过量93％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝252nm)；tr＝9.53and10.98min；[α]15 D＝-15.0(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.77(dd,J＝3.8,1.3Hz,1H),7.73(dd,J＝3.8,1.2Hz,1H),7.63(dd,J＝5.0,1.1Hz,1H),7.55(dd,J＝4.9,1.3Hz,1H),7.12(dd,J＝5.0,3.8Hz,1H),7.09(dd,J＝5.0,3.7Hz,1H),5.85(ddd,J＝17.2,10.4,7.6Hz,1H),5.30–5.08(m,2H),4.39(dd,J＝10.9,5.9Hz,1H),4.32(dd,J＝10.9,6.5Hz,1H),3.38–3.26(m,1H),3.16(dd,J＝16.1,6.2Hz,1H),3.05(dd,J＝16.1,7.4Hz,1H).13C NMR(101MHz,Chloroform-d)δ190.9,161.9,144.3,136.9,133.9,133.5,133.4,132.5,132.0,128.1,127.7,117.1,66.8,40.7,38.8.HRMS(ESI+)计算值C15H15O3S2 +([M+H]+):307.0457,测量值:307.0453。
实施例18
的制备
在25mL反应管中加入0.010mmol[Ir(COD)Cl]2、0.020mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.02mmol)。在25℃氮气保护下，依次加入0.20mmol 1,3-二环己基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率89％,产物的对映选择性通过产物与对溴苯甲酸甲酯发生Heck偶联反应的得到的衍生物测定。手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak AD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝9.29and 10.98min；[α]15 D＝1.3(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.69(ddd,J＝17.6,10.4,7.6Hz,1H),5.13–5.03(m,2H),4.06(dd,J＝10.8,6.2Hz,1H),3.97(dd,J＝10.8,6.0Hz,1H),3.04–2.92(m,1H),2.57(dd,J＝16.8,6.0Hz 1H),2.51(dd,J＝17.2,7.6Hz,1H),2.36–2.23(m,2H),1.95–1.61(m,10H),1.51–1.15(m,10H).13C NMR(101MHz,Chloroform-d)δ211.8,175.9,137.6,116.4,65.9,51.1,43.1,41.9,37.8,29.0,28.3,28.2,25.8,25.7,25.59,25.56,25.4.HRMS(ESI+)计算值C19H31O3 +([M+H]+):307.2268,测量值:307.2273。
实施例19
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol乙酰丙酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率75％,产物的对映选择性通过产物与苯乙烯发生烯烃复分解反应的得到的衍生物测定。手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝9.04and 10.85min；[α]15 D＝9.6(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.70(ddd,J＝17.6,10.4,7.6Hz,1H),5.16–5.04(m,2H),4.10(dd,J＝10.9,6.1Hz,1H),3.97(dd,J＝10.9,6.6Hz,1H),3.05–2.91(m,1H),2.59(dd,J＝16.7,6.2Hz,1H),2.51(dd,J＝16.8,7.5Hz,1H),2.16(s,3H),2.04(s,3H).13C NMR(101MHz,Chloroform-d)δ206.7,170.9,137.2,116.7,66.3,45.0,38.0,30.5,20.8.HRMS(ESI+)计算值C9H15O3 +([M+H]+):171.1016,测量值:171.1022。
实施例20
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol1,3-二环丙基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率90％,产物的对映选择性通过产物与苯乙烯发生烯烃复分解反应的得到的衍生物测定。手性高效液相色谱测定产物的对映选择性过量96％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝7.10and 8.29min；[α]15 D＝-0.7(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.73(ddd,J＝17.2,10.4,7.5Hz,1H),5.20–5.04(m,2H),4.09(dd,J＝10.9,6.2Hz,1H),4.01(dd,J＝10.9,6.4Hz,1H),3.09–2.97(m,1H),2.73(dd,J＝16.4,6.1Hz,1H),2.63(dd,J＝16.4,7.6Hz,1H),1.98–1.87(m,1H),1.64–1.56(m,1H),1.06–1.01(m,2H),1.01–0.96(m,2H),0.91–0.82(m,4H).13C NMR(101MHz,Chloroform-d)δ208.8,174.7,137.4,116.5,66.3,44.8,38.2,20.9,12.8,10.84,10.78,8.4.HRMS(ESI+)计算值C13H19O3 +([M+H]+):223.1329,测量值:223.1322。
实施例21
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-氟-1,3-二苯基丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率98％,手性高效液相色谱测定主要产物的对映选择性过量99％，HPLC(ChiralpakAS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝6.00and9.33min；次要产物的对映选择性过量99％，tr＝7.01and 15.60min；[α]15 D＝7.3(c 1.00,CH2Cl2)；核磁测定非对映选择性3.8:1,1H NMR(400MHz,Chloroform-d)(dr＝3.8:1)major:7.97–7.83(m,4H),7.66–7.50(m,2H),7.49–7.34(m,4H),5.91(ddd,J＝17.3,10.5,8.6Hz,1H),5.64(dd,J＝48.2,4.8Hz,1H),5.39–5.25(m,2H),4.52(d,J＝6.4Hz,2H),3.53–3.36(m,1H).minor:δ8.09–8.01(m,0.53H),7.97–7.83(m,0.50H),7.66–7.50(m,0.6H),7.49–7.34(m,1.12H),δ6.01–5.76(m,0.51H),δ5.25–5.09(m,0.54H),4.52(d,J＝0.52Hz,2H),3.53–3.36(m,0.24H).13C NMR(101MHz,Chloroform-d)δ195.4(d,J＝19.9Hz),166.1,134.6,133.8,133.3,133.0,132.9,132.8,129.7,129.59,129.57,129.0,128.8,128.7,128.5,128.3,121.0,119.9,93.7(d,J＝191.4Hz),62.7(d,J＝6.1Hz),45.9(d,J＝19.7Hz).19F NMR(376MHz,Chloroform-d)(dr＝3.8:1)major:δ-196.33(dd,J＝48.2,22.7Hz),minor:-202.57(dd,J＝48.6,29.5Hz).HRMS(ESI+)计算值C19H18FO3 +([M+H]+):313.1234,测量值:313.1244。
实施例22
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基丁烷-1,3-二酮、0.4mmol4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物。产物1的产率为18％。手性高效液相色谱测定产物的对映选择性过量92％，HPLC(ChiralcelOJ-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝242nm)；[α]25 D＝-3.5(c1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ7.99–7.91(m,2H),7.63–7.53(m,1H),7.51–7.43(m,2H),5.79(ddd,J＝17.6,10.4,7.3Hz,1H),5.19–5.04(m,2H),4.18(dd,J＝10.9,5.8Hz,1H),4.09(dd,J＝10.9,6.4Hz,1H),3.27–3.10(m,2H),3.05(dd,J＝16.5,7.2Hz,1H),2.01(s,3H).13C NMR(101MHz,Chloroform-d)δ198.2,170.9,137.4,137.0,133.2,128.6,128.0,116.7,66.5,39.9,38.3,20.8.HRMS(ESI+)计算值C14H20NO3 +([M+NH4]+):250.1438,测量值:250.1446。产物2的产率为68％。手性高效液相色谱测定产物的对映选择性过量96％，HPLC(Chiralcel OJ-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝230nm)；tr＝11.63and 12.30min；[α]25 D＝3.8(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.05–7.97(m,2H),7.61–7.52(m,1H),7.48–7.39(m,2H),5.79(ddd,J＝17.3,10.4,7.6Hz,1H),5.24–5.06(m,2H),4.34(dd,J＝10.9,6.1Hz,1H),4.24(dd,J＝10.9,6.4Hz,1H),3.20–3.09(m,1H),2.67(dd,J＝16.8,6.2Hz,1H),2.59(dd,J＝16.8,7.4Hz,1H),2.16(s,3H).13C NMR(101MHz,Chloroform-d)δ206.7,166.4,137.2,133.0,130.0,129.5,128.4,116.9,66.8,45.0,38.2,30.5.HRMS(ESI+)计算值C14H17O3 +([M+H]+):233.1172,测量值:233.1172。
实施例23
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-3-(吡啶-2-基)丙烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物。产物1的产率为47％。手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak AS-H,i-propanol/hexane＝2/98,flow rate 0.5mL/min,λ＝220nm)；tr＝20.77and22.05min；[α]25 D＝-12.0(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.66–8.64(m,1H),8.03–7.95(m,3H),7.85–7.74(m,1H),7.57–7.49(m,1H),7.48–7.35(m,3H),5.89(ddd,J＝17.5,10.4,7.3Hz,1H),5.27–5.05(m,2H),4.42(dd,J＝10.8,5.9Hz,1H),4.34(dd,J＝10.8,6.4Hz,1H),3.51(dd,J＝16.7,6.5Hz,1H),3.42(dd,J＝16.8,7.2Hz,1H),3.40–3.30(m,1H).13C NMR(101MHz,Chloroform-d)δ200.0,166.4,153.2,148.9,137.6,136.9,132.9,130.1,129.6,128.3,127.2,121.9,116.7,67.1,39.0,38.5.HRMS(ESI+)计算值C18H18NO3 +([M+H]+):296.1281,测量值:296.1277。产物2的产率为42％。手性高效液相色谱测定产物的对映选择性过量97％，HPLC(Chiralcel OJ-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝230nm)；tr＝42.40and 44.68min；[α]25 D＝-7.4(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.80–8.69(m,1H),8.11–8.02(m,1H),7.99–7.89(m,2H),7.87–7.78(m,1H),7.58–7.51(m,1H),7.49–7.38(m,3H),5.87(ddd,J＝18.0,10.4,7.6Hz,1H),5.29–5.05(m,2H),4.53(dd,J＝10.9,6.2Hz,1H),4.44(dd,J＝10.9,6.9Hz,1H),3.47–3.34(m,1H),3.26(dd,J＝16.8,5.9Hz,1H),3.15(dd,J＝16.8,7.5Hz,1H).13CNMR(101MHz,Chloroform-d)δ198.1,164.9,149.9,147.8,137.1,137.0,136.9,133.1,128.6,128.1,126.9,125.1,117.1,67.7,40.0,38.5.HRMS(ESI+)计算值C18H18NO3 +([M+H]+):296.1281,测量值:296.1288。
实施例24
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-环己基丁烷-1,3-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物。产物1的产率为19％。产物的对映选择性通过产物与苯乙烯发生烯烃复分解反应的得到的衍生物测定,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝5.67and 6.22min；[α]25 D＝1.2(c 0.80,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.70(ddd,J＝17.2,10.4,7.6Hz,1H),5.14–5.02(m,2H),4.09(dd,J＝10.8,6.2Hz,1H),3.97(dd,J＝10.8,6.3Hz,1H),3.09–2.94(m,1H),2.58(dd,J＝16.4,5.7Hz,1H),2.52(dd,J＝16.4,6.6Hz,1H),2.38–2.26(m,1H),2.04(s,3H),1.86–1.76(m,4H),1.37–1.21(m,6H).13C NMR(101MHz,Chloroform-d)δ211.8,170.9,137.6,116.4,66.4,51.1,42.0,37.7,28.3,25.8,25.6,25.58,20.8.HRMS(ESI+)计算值C14H23O3 +([M+H]+):239.1642,测量值:239.1649。产物2的产率为47％。产物的对映选择性通过产物与苯乙烯发生烯烃复分解反应的得到的衍生物测定,手性高效液相色谱测定产物的对映选择性过量97％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝254nm)；tr＝6.52and 7.14min；[α]25 D＝4.6(c 0.60,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.70(ddd,J＝17.2,10.5,7.6Hz,1H),5.20–5.00(m,2H),4.08(dd,J＝10.9,6.1Hz,1H),3.98(dd,J＝10.9,6.3Hz,1H),3.05–2.91(m,1H),2.58(dd,J＝16.6,6.1Hz,1H),2.50(dd,J＝16.7,7.6Hz,1H),2.28(tt,J＝11.3,3.7Hz,1H),2.15(s,3H),1.93–1.84(m,2H),1.79–1.69(m,2H),1.50–1.36(m,2H),1.35–1.08(m,4H).13C NMR(101MHz,Chloroform-d)δ206.8,175.9,137.3,116.7,65.9,45.0,43.1,38.2,30.5,29.0,25.7,25.4.HRMS(ESI+)计算值C18H18NO3 +([M+H]+):239.1642,测量值:239.1638。
实施例25
的制备/>
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 5,5-二甲基己烷-2,4-二酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应结束后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物。产物1的产率为18％。手性气相色谱测定产物的对映选择性过量97％，GC(Gamma DEX-225,N2 flow rate 1.0mL/min,60min at 80℃,then 1℃/min-1to 150℃)；tr＝99.92and101.66min；[α]25 D＝-1.2(c 0.30,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.62(ddd,J＝17.3,10.4,7.7Hz,1H),5.10–4.92(m,2H),4.02(dd,J＝10.8,6.2Hz,1H),3.91(dd,J＝10.8,6.2Hz,1H),3.03–2.86(m,1H),2.56(dd,J＝17.6,6.4Hz,1H),2.51(dd,J＝17.6,7.2Hz,1H),1.97(s,3H),1.06(s,9H).13C NMR(101MHz,Chloroform-d)δ213.5,171.0,137.7,116.4,66.4,44.2,38.0,37.6,26.2,20.9.HRMS(ESI+)计算值C14H23O3 +([M+H]+):239.1642,测量值:239.1649。产物2的产率为53％。手性气相色谱测定产物的对映选择性过量99％，GC(Gamma DEX-225,N2flow rate 1.0mL/min,60min at 80℃,then 1℃/min-1to150℃)；tr＝101.62and 102.69min；[α]25 D＝-1.5(c 1.00,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ5.63(ddd,J＝17.2,10.5,7.7Hz,1H),5.13–4.97(m,2H),4.00(dd,J＝10.9,6.2Hz,1H),3.91(dd,J＝10.9,6.1Hz,1H),2.98–2.85(m,1H),2.50(dd,J＝16.7,6.1Hz,1H),2.44(dd,J＝16.7,7.5Hz,1H),2.09(s,3H),1.12(s,9H).13C NMR(101MHz,Chloroform-d)δ206.7,178.3,137.3,116.6,66.1,44.9,38.8,38.2,30.5,27.1.HRMS(ESI+)计算值C12H20O3Na+([M+Na]+):235.1305,测量值:235.1299。
实施例26
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol苯甲酰乙酸叔丁酯、0.4mmol4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，苯甲酰乙酸叔丁酯反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L inTHF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率81％,手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralpak AD-H+ChiralpakAD-H,i-propanol/hexane＝2/98,flow rate 1.0mL/min,λ＝230nm)；tr＝21.61and24.69min；[α]15 D＝-3.2(c 0.51,CH2Cl2)；1H NMR(400MHz,Chloroform-d)δ8.07–7.99(m,2H),7.61–7.52(m,1H),7.49–7.40(m,2H),5.81(ddd,J＝17.2,10.4,7.7Hz,1H),5.25–5.06(m,2H),4.34(dd,J＝10.9,6.3Hz,1H),4.28(dd,J＝10.9,6.2Hz,1H),3.09–2.94(m,1H),2.51(dd,J＝15.2,6.0Hz,1H),2.37(dd,J＝15.2,8.4Hz,1H),1.44(s,9H).13C NMR(101MHz,Chloroform-d)δ171.0,166.3,137.1,133.0,130.1,129.6,128.3,116.9,80.7,66.7,39.6,37.4,28.1.HRMS(ESI+)计算值C17H23O4 +([M+H]+):291.1591,测量值:291.1575。
实施例27
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol乙酰乙酸叔丁酯、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，乙酰乙酸叔丁酯反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/LinTHF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率70％。产物的对映选择性通过产物与苯乙烯发生烯烃复分解反应的得到的衍生物测定,手性高效液相色谱测定产物的对映选择性过量93％，HPLC(Chiralpak AD-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝210nm)；tr＝4.81and 5.34min；[α]15 D＝-0.4(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ5.72(ddd,J＝17.4,10.4,7.7Hz,1H),5.21–5.09(m,2H),4.09(dd,J＝10.9,6.3Hz,1H),4.00(dd,J＝10.9,6.5Hz,1H),2.94–2.81(m,1H),2.40(dd,J＝15.2,6.1Hz,1H),2.27(dd,J＝15.2,8.3Hz,1H),2.05(s,3H),1.44(s,9H).13CNMR(101MHz,Chloroform-d)δ171.0,170.9,137.0,116.8,80.6,66.3,39.4,37.4,28.0,20.8.HRMS(ESI+)计算值C12H21O4 +([M+H]+):229.1436,测量值:229.1430。
实施例28
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol N,N-二甲基-3-氧代-3-苯基丙酰胺、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，N,N-二甲基-3-氧代-3-苯基丙酰胺反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率72％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝10.59and 14.55min；[α]15 D＝-2.8(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.09–7.99(m,2H),7.60–7.52(m,1H),7.48–7.40(m,2H),5.87(ddd,J＝17.2,10.4,7.6Hz,1H),5.26–5.10(m,2H),4.38(dd,J＝10.6,5.7Hz,1H),4.34(dd,J＝10.5,5.7Hz,1H),3.29–3.15(m,1H),3.01(s,3H),2.94(s,3H),2.58(dd,J＝15.5,6.6Hz,1H),2.47(dd,J＝15.6,7.1Hz,1H).13C NMR(101MHz,Chloroform-d)δ170.8,166.4,137.8,132.9,130.2,129.5,128.3,116.5,67.0,39.2,37.3,35.5,34.7.HRMS(ESI+)计算值C15H20NO3 +([M+H]+):262.1438,测量值:262.1431。
实施例29
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-(甲基磺酰基)-1-苯乙烷-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应完全后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率85％,手性高效液相色谱测定产物的对映选择性过量96％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝228nm)；tr＝20.16and23.11min；[α]15 D＝17.2(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.08–7.97(m,2H),7.62–7.55(m,1H),7.51–7.41(m,2H),5.86(ddd,J＝17.2,10.3,7.9Hz,1H),5.44–5.26(m,2H),4.45(dd,J＝11.1,5.4Hz,1H),4.37(dd,J＝11.0,6.1Hz,1H),3.36–3.25(m,2H),3.20(dd,J＝15.2,9.4Hz,1H),2.95(s,3H).13C NMR(101MHz,Chloroform-d)δ166.1,135.3,133.3,129.61,129.57,128.5,119.5,66.0,56.2,42.3,38.5.HRMS(ESI+)计算值C13H17O4S+([M+H]+):269.0842,测量值:269.0836。
实施例30
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-2-甲苯磺酸-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应完全后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率60％,手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralpak AD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝11.83and 12.92min；[α]15 D＝-4.6(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.00–7.91(m,2H),7.84–7.75(m,2H),7.61–7.54(m,1H),7.48–7.38(m,2H),7.32(d,J＝8.0Hz,2H),5.76(ddd,J＝17.2,10.4,7.8Hz,1H),5.23–5.10(m,2H),4.38(dd,J＝11.1,5.7Hz,1H),4.31(dd,J＝11.1,6.1Hz,1H),3.39(dd,J＝14.3,5.4Hz,1H),3.26(dd,J＝14.3,7.3Hz,1H),3.20–3.05(m,1H),2.43(s,3H).13C NMR(101MHz,Chloroform-d)δ166.0,144.9,136.5,135.3,133.2,129.9,129.7,129.5,128.4,128.1,118.3,65.8,57.4,38.1,21.6.HRMS(ESI+)计算值C19H21O4S+([M+H]+):345.1155,测量值:345.1155。
实施例31
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmolα-硝基苯乙酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，反应完全后，减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率78％,手性高效液相色谱测定产物的对映选择性过量99％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝230nm)；tr＝7.84and 8.79min；[α]15 D＝25.1(c0.80,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.06–7.95(m,2H),7.63–7.54(m,1H),7.51–7.41(m,2H),5.80(ddd,J＝17.2,10.4,8.0Hz,1H),5.38–5.26(m,2H),4.62(dd,J＝12.5,6.3Hz,1H),4.52(dd,J＝11.7,7.2Hz,1H),4.47(dd,J＝10.6,4.3Hz,1H),4.34(dd,J＝11.3,7.3Hz,1H),3.52–3.38(m,1H).13C NMR(101MHz,Chloroform-d)δ166.0,133.4,132.4,129.6,129.4,128.5,120.2,76.7,64.4,41.6.HRMS(ESI+)计算值C12H13NNaO4 +([M+Na]+):258.0737,测量值:258.0740。
实施例32
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-2-(吡啶-2-基)乙烷-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，1-苯基-2-(吡啶-2-基)乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率68％,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralpak AD-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝210nm)；tr＝6.70and 7.26min；[α]15 D＝-25.5(c 0.53,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.62–8.50(m,1H),8.06–7.94(m,2H),7.65–7.51(m,2H),7.48–7.36(m,2H),7.20–7.05(m,2H),5.84(ddd,J＝17.2,10.4,7.9Hz,1H),5.19–4.99(m,2H),4.34(s,1H),4.32(s,1H),3.23–3.11(m,1H),3.06(dd,J＝13.6,6.8Hz,1H),2.94(dd,J＝13.6,7.9Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.5,159.4,149.3,138.0,136.3,132.9,130.2,129.6,128.3,123.7,121.3,116.8,67.0,43.1,40.1.HRMS(ESI+)计算值C17H18NO2 +([M+H]+):268.1332,测量值:268.1329。
实施例33
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-(6-氟吡啶-2-基)1-苯乙烷-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，2-(6-氟吡啶-2-基)1-苯乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率94％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralcel OD-H,i-propanol/hexane＝5/95,flow rate 0.4mL/min,λ＝210nm)；tr＝20.00and 21.24min；[α]15 D＝-10.4(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.07–7.94(m,2H),7.74–7.61(m,1H),7.60–7.51(m,1H),7.49–7.39(m,2H),7.01(dd,J＝7.3,2.4Hz,1H),6.74(dd,J＝8.1,2.8Hz,1H),5.81(ddd,J＝17.2,10.4,7.9Hz,1H),5.17–5.00(m,2H),4.32(d,J＝6.0Hz,2H),3.24–3.11(m,1H),3.01(dd,J＝13.8,6.7Hz,1H),2.88(dd,J＝13.8,8.0Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.4,163.2(d,J＝239.8Hz),158.6(d,J＝13.3Hz),141.1(d,J＝8.1Hz),137.6,132.9,130.1,129.5,128.3,120.9(d,J＝4.3Hz),117.0,107.9(d,J＝37.5Hz),66.9,42.6,39.4.19F NMR(376MHz,Chloroform-d)δ-67.3(d,J＝8.3Hz).HRMS(ESI+)计算值C17H16FNNaO2 +([M+Na]+):308.1057,测量值:308.1050。
实施例34
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmolα-(2-吡嗪-基)苯乙酮、0.4mmol4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，α-(2-吡嗪-基)苯乙酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率70％,手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralpak IE,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝12.96and 15.75min；[α]15 D＝-6.5(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.51(dd,J＝2.6,1.5Hz,1H),8.45(d,J＝1.5Hz,1H),8.40(d,J＝2.6Hz,1H),8.07–7.93(m,2H),7.63–7.51(m,1H),7.49–7.39(m,2H),5.81(ddd,J＝17.0,10.5,7.8Hz,1H),5.16–4.99(m,2H),4.36(dd,J＝6.0,1.4Hz,2H),3.23–3.14(m,1H),3.11(dd,J＝13.5,6.0Hz,1H),2.95(dd,J＝13.6,8.1Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.3,155.2,145.1,144.1,142.4,137.1,133.0,130.0,129.5,128.3,117.5,66.9,42.8,37.2.HRMS(ESI+)计算值C16H17N2O2 +([M+H]+):269.1285,测量值:269.1281。
实施例35
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-2-(嘧啶-4-基)乙烷-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，1-苯基-2-(嘧啶-4-基)乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率79％,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝8.04and 9.17min；[α]15 D＝-2.9(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ9.14(d,J＝1.3Hz,1H),8.60(d,J＝5.1Hz,1H),8.05–7.91(m,2H),7.65–7.51(m,1H),7.49–7.39(m,2H),7.18(dd,J＝5.2,1.4Hz,1H),5.90–5.68(m,1H),5.23–5.01(m,2H),4.35(dd,J＝6.2,3.4Hz,2H),3.27–3.14(m,1H),3.06(dd,J＝13.9,6.3Hz,1H),2.90(dd,J＝13.9,8.3Hz,1H).13C NMR(101MHz,Chloroform-d)δ168.2,166.3,158.6,156.6,136.9,133.1,130.0,129.5,128.4,121.4,117.6,66.9,42.3,39.6.HRMS(ESI+)计算值C16H17N2O2 +([M+H]+):269.1285,测量值:269.1279。
实施例36
的制备
在25mL反应管中加入0.005mmol[Ir(COD)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-2-(喹啉-4-基)乙烷-1-酮、0.4mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，1-苯基-2-(喹啉-4-基)乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率78％,手性高效液相色谱测定产物的对映选择性过量93％，HPLC(Chiralpak AD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝210nm)；tr＝5.57and 6.56min；[α]15 D＝-11.7(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.05(dd,J＝8.5,3.4Hz,2H),7.99–7.92(m,2H),7.76(dd,J＝8.2,1.5Hz,1H),7.73–7.65(m,1H),7.57–7.44(m,2H),7.42–7.33(m,2H),7.29(d,J＝8.5Hz,1H),5.90(ddd,J＝17.7,10.4,7.6Hz,1H),5.19–5.02(m,2H),4.39(d,J＝6.2Hz,2H),3.37–3.27(m,1H),3.25(dd,J＝13.2,6.8Hz,1H),3.16(dd,J＝13.4,7.7Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.4,160.0,147.8,137.9,136.3,132.9,130.1,129.51,129.47,128.8,128.2,127.5,126.8,125.9,122.0,116.9,67.2,43.0,40.9.HRMS(ESI+)计算值C21H20NO2 +([M+H]+):318.1489,测量值:318.1488。
实施例37
的制备/>
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-(苯并[d]恶唑-2-基)-1-苯乙烷-1-酮、0.6mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，2-(苯并[d]恶唑-2-基)-1-苯乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率82％,手性高效液相色谱测定产物的对映选择性过量92％，HPLC(Chiralpak AD-H,i-propanol/hexane＝10/90,flow rate 1.0mL/min,λ＝230nm)；tr＝8.22and 9.33min；[α]15 D＝-11.9(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ7.99–7.91(m,2H),7.70–7.63(m,1H),7.56–7.49(m,1H),7.48–7.42(m,1H),7.41–7.33(m,2H),7.32–7.27(m,2H),5.89(ddd,J＝17.2,10.4,7.7Hz,1H),5.31–5.06(m,2H),4.47(dd,J＝11.0,5.7Hz,1H),4.39(dd,J＝11.0,6.6Hz,1H),3.38–3.27(m,1H),3.23(dd,J＝15.1,6.5Hz,1H),3.14(dd,J＝15.1,7.8Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.3,164.9,150.8,141.2,136.4,133.0,129.8,129.5,128.3,124.6,124.2,119.6,117.8,110.3,66.7,41.0,31.0.HRMS(ESI+)计算值C19H18NO3 +([M+H]+):308.1281,测量值:308.1278。
实施例38
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-(1-甲基苯并[d]咪唑-2-基)-1-苯乙烷-1-酮、0.6mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，2-(1-甲基苯并[d]咪唑-2-基)-1-苯乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率74％,手性高效液相色谱测定产物的对映选择性过量99％，HPLC(Chiralpak IA,i-propanol/hexane＝20/80,flow rate1.0mL/min,λ＝210nm)；tr＝8.53and 10.10min；[α]15 D＝-5.7(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.00–7.88(m,2H),7.77–7.68(m,1H),7.57–7.49(m,1H),7.42–7.32(m,2H),7.30–7.23(m,3H),5.92(ddd,J＝17.2,10.4,7.8Hz,1H),5.27–5.07(m,2H),4.46(dd,J＝10.1,5.0Hz,1H),4.42(dd,J＝10.1,5.3Hz,1H),3.73(s,3H),3.48–3.20(m,1H),3.20(dd,J＝14.9,7.1Hz,1H),3.08(dd,J＝14.9,7.5Hz,1H).13C NMR(101MHz,Chloroform-d)δ166.4,152.8,137.0,135.5,133.0,129.9,129.5,128.4,122.3,122.2,119.1,117.5,109.1,66.8,41.9,30.0,29.5.HRMS(ESI+)计算值C20H21N2O2 +([M+H]+):321.1598,测量值:321.1595。
实施例39
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 1-苯基-2-(噻唑-2-基)乙烷-1-酮、0.6mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，1-苯基-2-(噻唑-2-基)乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率66％,手性高效液相色谱测定产物的对映选择性过量95％，HPLC(Chiralpak AD-H,i-propanol/hexane＝5/95,flow rate 0.5mL/min,λ＝230nm)；tr＝29.65and 32.06min；[α]15 D＝1.9(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.07–7.96(m,2H),7.70(d,J＝3.4Hz,1H),7.60–7.52(m,1H),7.48–7.40(m,2H),7.20(d,J＝3.3Hz,1H),5.85(ddd,J＝17.2,10.4,7.6Hz,1H),5.23–5.11(m,2H),4.39(dd,J＝10.8,6.0Hz,1H),4.35(dd,J＝11.2,6.0Hz,1H),3.33(dd,J＝14.4,6.1Hz,1H),3.21(dd,J＝14.4,7.8Hz,1H),3.18–3.09(m,1H).13C NMR(101MHz,Chloroform-d)δ167.9,166.4,142.3,136.9,133.0,130.0,129.6,128.4,118.5,117.8,66.6,43.4,35.0.HRMS(ESI+)计算值C15H16NSO2 +([M+H]+):274.0896,测量值:274.0894。
实施例40
的制备
在25mL反应管中加入0.005mmol[Ir(DBCOT)Cl]2、0.010mmol(S,S,S)-L1、0.5mL除氧THF和0.5mL除氧正丙胺，50℃下反应30分钟后在减压条件下蒸去溶剂得到铱催化剂(或使用金属铱盐和手性配体、高氯酸银、4-乙烯基-1,3-二氧环戊-2-酮制备铱络合物，铱络合物用量为0.01mmol)。在25℃氮气保护下，依次加入0.20mmol 2-(苯并[d]噻唑-2-基)-1-苯乙烷-1-酮、0.6mmol 4-乙烯基-1,3-二氧环戊-2-酮和0.20mmol碳酸铯和2mL二氯甲烷，在25℃下反应。通过薄层色谱监测反应，2-(苯并[d]噻唑-2-基)-1-苯乙烷-1-酮反应完全后，往体系中加入2mL四丁基氟化铵(1.0mol/L in THF),40℃下反应24小时。减压下除去溶剂之后通过硅胶柱层析纯化得到产物，产率86％,手性高效液相色谱测定产物的对映选择性过量94％，HPLC(Chiralcel OD-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝220nm)；tr＝7.10and 10.33min；[α]15 D＝-4.6(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.02–7.94(m,3H),7.86–7.79(m,1H),7.58–7.49(m,1H),7.49–7.43(m,1H),7.44–7.31(m,3H),5.89(ddd,J＝17.3,10.4,7.6Hz,1H),5.27–5.09(m,2H),4.45(dd,J＝11.0,5.7Hz,1H),4.39(dd,J＝11.1,6.0Hz,1H),3.46–3.36(m,1H),3.34–3.20(m,2H).13CNMR(101MHz,Chloroform-d)δ169.1,166.3,153.1,136.7,135.2,133.0,129.9,129.5,128.3,126.0,124.9,122.6,121.5,117.9,66.7,43.1,36.2.HRMS(ESI+)计算值C19H18NSO+([M+H]+):324.1053,测量值:324.1049。
实施例41
的制备
将火焰干燥的Schlenk瓶冷却至室温并抽真空并用氩气回填3次。向该Schlenk瓶中加入实施例31所得产物(所用手性配体为(R,R,R)-L1)(4.77mmol,1.0equiv.)和锌粉(23.85mmol,5.0equiv.)。并通过注射器将乙酸(24mL)转移到该瓶中。将反应在35℃搅拌30小时。一旦原料耗尽(通过TLC监测)，反应混合物通过硅藻土过滤。蒸发乙酸并将残余物溶解在乙酸乙酯中。混合物用饱和碳酸氢钠水溶液洗涤直至乙酸完全耗尽。分离有机层并蒸发得到伯胺。将伯胺溶解在二氯甲烷(24mL)中。将所得溶液冷却至–5℃，然后加入三乙胺(9.54mmol，2.0equiv.)。然后在5分钟内逐滴加入丙烯酰氯(7.95mmol，1.67equiv.)。将反应混合物在–5℃下搅拌10分钟，然后在室温下搅拌6小时。室温搅拌6小时后，反应用饱和氯化铵水溶液淬灭并用二氯甲烷萃取。有机层用盐水洗涤，用无水硫酸钠干燥并真空浓缩。产物通过硅胶柱色谱纯化，得到化合物。产率49％,[α]15 D＝-9.1(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ8.07–7.97(m,2H),7.61–7.54(m,1H),7.49–7.41(m,2H),6.29(dd,J＝17.0,1.4Hz,1H),6.10(dd,J＝17.0,10.3Hz,1H),5.94(s,1H),5.79(ddd,J＝17.3,10.4,8.0Hz,1H),5.65(dd,J＝10.3,1.4Hz,1H),5.33–5.17(m,2H),4.46(dd,J＝11.2,5.4Hz,1H),4.31(dd,J＝11.2,6.2Hz,1H),3.62–3.51(m,1H),3.47–3.36(m,1H),2.86–2.71(m,1H).13C NMR(101MHz,Chloroform-d)δ166.7,165.6,135.7,133.2,130.7,129.8,129.6,128.5,126.6,118.5,65.2,43.2,40.0.HRMS(ESI+)计算值C15H18NO3 +([M+H]+):260.1277,测量值:260.1281。
实施例42
的制备
向圆底烧瓶中加入氢氧化钠(7.2mmol，5.0equiv.)的水(15mL)溶液。在0℃加入实施例41所得产物(1.44mmol,1.0equiv.)的甲醇(2mL)溶液。将所得溶液在0℃搅拌45分钟。通过加入1.5M硫酸水溶液将溶液酸化至pH＝4.0。溶液用饱和氯化钠水溶液并用乙醚(10mL×3)萃取。合并的有机层用无水硫酸钠干燥并减压蒸发，得到伯醇。在0℃向搅拌的伯醇的DMF的溶液中加入氢化钠(5.04mmol，3.5equiv.)。将混合物在室温搅拌30分钟，然后加入溴化苄(5.76mmol，4.0equiv.)。将反应在室温搅拌直至起始材料完全消耗。接下来，将其冷却至0℃并用饱和氯化铵水溶液处理。分离有机相，水相用乙醚萃取3次。合并的有机相用无水硫酸钠干燥并真空除去溶剂。残余物通过硅胶柱色谱法纯化，得到化合物。产率59％,手性高效液相色谱测定产物的对映选择性过量97％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate 1.0mL/min,λ＝254nm)；tr＝7.55and 8.30min；[α]15 D＝-17.3(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ＝7.38–7.20(m,9H),7.13(d,J＝6.8Hz,1H),6.71(dd,J＝17.2,10.8Hz,0.5H),6.49(dd,J＝16.8,10.0Hz,0.5H),6.39(ddd,J＝28.0,16.8,2.4Hz,1H),5.88–5.71(m,1H),5.66(ddd,J＝22.4,10.4,2.4Hz,1H),5.19–5.06(m,2H),4.75(d,J＝14.8Hz,0.5H),4.70–4.56(m,1.5H),4.53–4.41(m,2H),3.61(dd,J＝15.2,6.4Hz,0.5H),3.57–3.43(m,2.5H),3.39(dd,J＝9.2,6.0Hz,0.5H),3.25(dd,J＝15.2,8.0Hz,0.5H),2.95–2.82(m,0.5H),2.72–2.60(m,0.5H).13C NMR(101MHz,Chloroform-d)δ167.2,166.8,138.2,137.9,137.6,137.5,137.0,136.4,128.8,128.5,128.44,128.36,128.3,128.1,127.8,127.7,127.6,127.5,127.3,126.9,126.3,118.0,117.1,73.2,73.0,71.6,70.5,51.9,49.3,48.3,48.1,44.3,43.0.HRMS(ESI+)计算值C22H25NO2 +([M+H]+):336.1957,测量值:336.1958。
实施例43
的制备
将实施例42得到的丙烯酰胺(0.30mmol，1.0equiv.)和Grubbs第二代催化剂(0.015mmol，0.05equiv.)在二氯甲烷(15mL)中的溶液回流5小时。将反应混合物真空浓缩，残余物通过硅胶快速色谱法纯化，得到二氢吡啶酮。产率82％,手性高效液相色谱测定产物的对映选择性过量97％，HPLC(Chiralpak AS-H,i-propanol/hexane＝20/80,flow rate1.0mL/min,λ＝252nm)；tr＝25.56and 30.67min；[α]15 D＝118.9(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ7.39–7.26(m,8H),7.23–7.16(m,2H),6.42(dd,J＝9.8,4.3Hz,1H),6.01(dd,J＝9.8,1.7Hz,1H),4.71(d,J＝14.6Hz,1H),4.45(d,J＝14.6Hz,1H),4.31(d,J＝2.1Hz,2H),3.44–3.30(m,3H),3.28–3.20(m,1H),2.77–2.62(m,1H).13C NMR(101MHz,Chloroform-d)δ163.9,139.9,137.7,137.3,128.6,128.4,128.3,127.8,127.7,127.5,126.1,73.2,69.3,49.7,46.7,35.2.HRMS(ESI+)计算值C15H18NO3 +([M+H]+):308.1640,测量值:308.1645。
实施例44
的制备
向圆底烧瓶中加入水(1.0mL)、浓硫酸(0.3mL)、1,4-二氧六环(1.0mL)和实施例27得到的产物(1.0mmol)。将混合物加热至80℃并搅拌12小时，此时TLC显示原料完全转化。将反应混合物冷却至室温并用水(2.0mL)稀释。混合物用二氯甲烷(5×5mL)萃取，合并的有机相用盐水洗涤，并用无水硫酸钠干燥。过滤并浓缩滤液，粗产物通过快速柱色谱法纯化。产率90％,手性气相色谱测定产物的对映选择性过量97％，GC(Alpha DEX-120,N2flow rate1.0mL/min,20min at 80℃,then 0.5℃·min-1to 100℃)；tr＝40.00and 40.35min；[α]25 D＝1.3(c 1.00,CH2Cl2).1H NMR(400MHz,Chloroform-d)δ5.78(ddd,J＝17.5,10.3,7.6Hz,1H),5.27–5.11(m,2H),4.44(dd,J＝9.0,7.6Hz,1H),4.02(dd,J＝9.1,7.9Hz,1H),3.32–3.13(m,1H),2.67(dd,J＝17.4,8.4Hz,1H),2.39(dd,J＝17.4,8.9Hz,1H).13C NMR(101MHz,Chloroform-d)δ176.5,135.7,117.5,72.2,39.8,34.1.HRMS(ESI+)计算值C6H8O2Na+([M+Na]+):135.0417,测量值:135.0422。
以上仅为本发明较佳的实施例，并非因此限制本发明的实施方式及保护范围，对于本领域技术人员而言，应当能够意识到凡运用本发明说明书内容所作出的等同替换和显而易见的变化所得到的方案，均应当包含在本发明的保护范围内。

Claims (5)

1.一种β-官能团化手性高烯丙醇衍生物的制备方法，包括以下步骤：
在惰性气体保护下，向溶剂中加入底物1、底物2、铱催化剂、0.01～10当量的碱，于在-20～110℃反应0.1～96小时，即得到β-官能团化手性高烯丙醇衍生物，反应式如下：
其中，*表示手性碳原子的位置；
所述反应式中，
产物选自/>
中的一种；
其中，R1、R2和R3的定义与上述产物的结构式相对应；
当R2为酯基、取代的酰胺基、取代或未取代的杂芳基时，所述制备方法还包括：对反应体系内的底物1的含量进行监测，当所述底物1完全转化后，向反应体系内加入四丁基氟化铵，并于25～60℃继续反应0.1～96小时；所述四丁基氟化铵的用量为底物1的2～20当量；
所述碱选自碱金属碳酸盐或有机碱；
所述铱催化剂为铱络合物，所述铱络合物的制备方法包括：在20℃条件，将金属铱盐和手性配体L以1:2摩尔比溶于四氢呋喃中，反应0.5～1小时，加入2个当量的高氯酸银置换阴离子，随后加入4个当量的4-乙烯基-1,3-二氧环戊-2-酮，20℃反应20小时，将产物通过柱层析分离得到铱络合物；
所述金属铱盐选自[Ir(COD)Cl]2或[Ir(DBCOT)Cl]2；
所述手性配体L的结构式选自
2.根据权利要求1所述的制备方法，其特征在于，所述底物1的浓度范围为0.001～3.0M，所述底物1与底物2的摩尔比为1:2～10；所述铱催化剂的用量为底物1的0.0001～10mol％。
3.根据权利要求1所述的制备方法，其特征在于，所述溶剂选自甲醇、乙醇、异丙醇、叔丁醇、仲丁醇、乙酸乙酯、乙酸异丁酯、乙酸异丙酯、正己烷、环己烷、正庚烷、丙酮、丁酮、乙醚、甲基叔丁基醚、甲基环戊基醚、甲基四氢呋喃、四氢呋喃、乙腈、二氯甲烷、三氯甲烷、1,2-二氯乙烷、二甲亚砜、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、甲苯和二氧六环中的一种或多种的组合。
4.一种Taniguchi lactone的制备方法，其特征在于，
将权利要求1所述的β-官能团化手性高烯丙醇衍生物置于浓硫酸中于50～110℃的条件下加热，所述β-官能团化手性高烯丙醇衍生物中，R1和R2的定义与权利要求1一致，R3为H；得到Taniguchi lactone，反应式如下：
5.一种cytisine合成前体的制备方法，其特征在于，包括以下步骤：
S1、将权利要求1所述的β-官能团化手性高烯丙醇衍生物在醋酸中加热，所述β-官能团化手性高烯丙醇衍生物I中，R1为苯基，R3为H，R2为硝基；加入锌粉，还原得到伯胺；将所述伯胺在二氯甲烷与三乙胺的存在下与丙烯酰氯反应得到酰胺，反应式如下：
S2、将步骤S1制得的酰胺在氢氧化钠中水解得到伯醇；将所述伯醇在氢化钠的作用下，与溴化苄反应得到苄基取代的丙烯酰胺，反应式如下：
S3、将步骤S2制得的苄基取代的丙烯酰胺在GrubbsII催化剂的存在下，在二氯甲烷中加热反应，反应得到cytisine合成前体环状丙烯酰胺，反应式如下：
CN202210904637.8A 2022-07-29 2022-07-29 β-官能团化手性高烯丙醇衍生物及其制备方法与应用 Active CN115093323B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210904637.8A CN115093323B (zh) 2022-07-29 2022-07-29 β-官能团化手性高烯丙醇衍生物及其制备方法与应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210904637.8A CN115093323B (zh) 2022-07-29 2022-07-29 β-官能团化手性高烯丙醇衍生物及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN115093323A CN115093323A (zh) 2022-09-23
CN115093323B true CN115093323B (zh) 2023-12-22

Family

ID=83300250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210904637.8A Active CN115093323B (zh) 2022-07-29 2022-07-29 β-官能团化手性高烯丙醇衍生物及其制备方法与应用

Country Status (1)

Country Link
CN (1) CN115093323B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62209033A (ja) * 1986-03-09 1987-09-14 Kuraray Co Ltd ２−メチレン−１，４−ジオ−ル類の製造方法
CN102093167A (zh) * 2010-12-10 2011-06-15 浙江大学 一种制备高烯丙醇或高炔丙醇的方法
CN111138443A (zh) * 2019-12-23 2020-05-12 上海金和生物制药有限公司 一种4’-去甲基表鬼臼毒素全合成的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62209033A (ja) * 1986-03-09 1987-09-14 Kuraray Co Ltd ２−メチレン−１，４−ジオ−ル類の製造方法
CN102093167A (zh) * 2010-12-10 2011-06-15 浙江大学 一种制备高烯丙醇或高炔丙醇的方法
CN111138443A (zh) * 2019-12-23 2020-05-12 上海金和生物制药有限公司 一种4’-去甲基表鬼臼毒素全合成的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A Modular Approach to the Asymmetric Synthesis of Cytisine";Struth, Felix R.等;《European Journal of Organic Chemistry》(第5期);第958-964页 *
"Cytisine: a natural product lead for the development of drugs acting at nicotinic acetylcholine receptors";Pérez, E. G.等;《Nat. Prod. Rep》;第29卷(第5期);第555-557页 *
"改良的Mosher法测定高烯丙醇的绝对构型";杨皓然 等;《化学研究》;第29卷(第02期);第152-159页 *
"氮杂环卡宾和金属配合物共催化构筑高烯丙醇化合物";何金梅 等;《西安科技大学学报》;第32卷(第06期);第743-747页 *

Also Published As

Publication number Publication date
CN115093323A (zh) 2022-09-23

Similar Documents

Publication Publication Date Title
US20120157658A1 (en) Methods, compositions, and apparatuses for forming macrocyclic compounds
Hormuth et al. Stereoselective synthesis of 3 (2H)-dihydrofuranones by addition of lithiated methoxyallene to chiral aldehydes
CN110078605B (zh) 有机硼酸与α,β-不饱和酮的不对称共轭加成反应合成光学活性三氟甲基化合物的方法
Su et al. Catalytic Enantioselective Intramolecular Oxa-Michael Reaction to α, β-Unsaturated Esters and Amides
CN115093323B (zh) β-官能团化手性高烯丙醇衍生物及其制备方法与应用
Zhu et al. Hydrogen-Bond-Assisted sequential reaction of silyl glyoxylates: Stereoselective synthesis of silyl enol ethers
CN113912577A (zh) 洛克米兰醇中间体、洛克米兰醇及其衍生物和制备与应用
CN111925356B (zh) 手性喹啉-咪唑啉配体的合成方法及其应用
CN104557583A (zh) 一种合成γ-氨基丁酸类手性化合物的方法
Corey et al. Improved enantioselective dihydroxylation of bishomoallylic alcohol derivatives using a mechanistically inspired bis-Cinchona alkaloid catalyst
WO2024017221A1 (zh) 含三级立体中心的α-叠氮酮的合成方法
CN110294702B (zh) 一种手性α-含氟高烯丙胺衍生物及其制备方法和应用
WO2007011910A2 (en) Chiral amine-catalyzed asymmetric addition of carbon-centered nucleophiles to imines
Xianming et al. Acid catalyzed ring-opening reactions of optically pure 2-aryl-3, 3-dimethyloxetanes
Terashima et al. Syntheses of α-CF 3-α-quaternary ketones via p-quinone methides and their derivatization to compounds with successively congested stereogenic centers
CN111689887A (zh) 铜/铱协同催化不对称烯丙基化/2-氮杂-Cope重排反应及其应用
CN113045530B (zh) 一种钌催化制备萘并吡喃类化合物的方法
CN115850304A (zh) 立体选择性制备2-烷基-4-硼基杂环类化合物的方法
CN110330429A (zh) 一种手性β-羟基酸酯化合物的制备方法
CN111499542A (zh) 一种含α-氰基取代季碳中心的环烯酮化合物的制备方法
JP5134883B2 (ja) フッ素置換基を持つ不斉触媒と光学活性化合物の製造方法
JPH06345777A (ja) ジイソピノカンフェニルクロロボランのインシトゥー製造
Han A Pd-catalysed Decarboxylative Route to Functionalized Nitrogen Heterocycles
CN114671816B (zh) 一种轴手性芳基三氮唑类化合物的制备方法
KR20000011595A (ko) 키랄락톤의제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant